Moreover, the availability of synthetic ANP (Anaritide or Carperitide) and BNP (Nesiritide) which has already been studied for heart failure treatment [53], let us to hypothesize NPs as novel repurposable biomolecular candidates for prostate cancer with a potential rapid bench to bedside transition. The gene discussed is NPPB; the disease is prostate carcinoma.